Avidity Biosciences RNA Revolution 2022

Avidity Biosciences presents its RNA therapeutic delivery platform and development strategy. The company is advancing multiple programs based on its proprietary AOC (Antibody Oligonucleotide Conjugate) platform, targeting RNA-based diseases with preclinical and early-stage clinical candidates.